CEL-SCI Corporation
501 articles about CEL-SCI Corporation
-
CEL-SCI Corporation Reports First Quarter Fiscal 2024 Financial Results
2/15/2024
CEL-SCI Corporation reported financial results for the quarter ended December 31, 2023, as well as key recent clinical and corporate developments.
-
CEL-SCI Announces Closing of $7.75 Million Public Offering of Common Stock
2/13/2024
CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a Phase 3 cancer immunotherapy company, today announced the closing of its previously announced public offering of 3,875,000 shares of its common stock at a public offering price of $2.00 per share, for gross proceeds of $7.75 million, before deducting underwriting discounts and offering expenses.
-
CEL-SCI Announces Pricing of $7.75 Million Public Offering of Common Stock
2/9/2024
CEL-SCI Corporation today announced the pricing of an offering of 3,875,000 shares of its common stock at an offering price of $2.00 per share, for gross proceeds of $7.75 million, before deducting underwriting discounts and offering expenses.
-
CEL-SCI Completes Commissioning of Its Multikine Manufacturing Facility for Commercial Scale Production of Head & Neck Cancer Drug
2/6/2024
CEL-SCI Corporation reported that its Multikine® * cGMP state-of-the-art dedicated manufacturing facility commissioning has been completed.
-
European Medicines Agency Grants CEL-SCI a Waiver of Strict Pediatric Requirements, Clearing the Path Towards Marketing Authorization for Multikine®
1/31/2024
CEL-SCI Corporation (NYSE American: CVM) today announced that the European Medicines Agency (EMA) Paediatric Committee granted CEL-SCI a product-specific waiver of strict requirements for commercialization of cancer drugs in the European Union (EU).
-
CEL-SCI Reports Fiscal 2023 Financial Results and Clinical & Corporate Developments
12/22/2023
CEL-SCI Corporation (NYSE American: CVM) reported financial results for the fiscal year ended September 30, 2023, as well as key clinical and corporate developments.
-
UK’S National Institute for Health and Care Excellence (NICE) Selects CEL-SCI’s Multikine as Potential New Standard of Care for Head & Neck Cancer
12/4/2023
CEL-SCI Corporation announced that the British National Institute for Health and Care Excellence has selected Multikine* to be evaluated as the potential new standard of care for squamous cell carcinoma of the head and neck in the UK.
-
CEL-SCI Announces Closing of $5 Million Public Offering of Common Stock - November 20, 2023
11/20/2023
CEL-SCI Corporation announced the closing of its previously announced public offering of 2,490,000 shares of its common stock to a single investor at a public offering price of $2.00 per share, for gross proceeds of approximately $5 million, before deducting underwriting discounts and offering expenses.
-
CEL-SCI Announces Pricing of $5 Million Offering of Common Stock
11/16/2023
CEL-SCI Corporation today announced the pricing of an offering of 2,490,000 shares of its common stock to a single investor at an offering price of $2.00 per share, for gross proceeds of approximately $5 million, before deducting underwriting discounts and offering expenses.
-
CEL-SCI Releases Video Detailing Recent Phase 3 Findings & its Plans to Seek Immediate Regulatory Approvals
10/24/2023
CEL-SCI Corporation (NYSE American: CVM) today released a video presentation in which the Company’s CEO, Geert Kersten, shares the most recent data presented at the European Society for Medical Oncology (ESMO) Congress and the data’s impact on propelling the Company’s immunotherapy drug Multikine*.
-
5-Year Head & Neck Cancer Survival Increased From 45% to 73% in CEL-SCI’s Target Population, Cutting Risk of Death in Half, as Presented at Leading Cancer Conference ESMO 2023
10/23/2023
CEL-SCI Corporation announced that it has finalized the selection criteria for the head and neck cancer target population to be treated with the Company’s immunotherapy drug Multikine.
-
CEL-SCI Readies Its Multikine Manufacturing Facility for Commercial Scale Production
10/19/2023
CEL-SCI Corporation reported that its Multikine* cGMP state-of-the-art dedicated manufacturing facility commissioning is substantially complete, a significant milestone toward a planned Biologics License Application with several regulatory agencies for approval of Multikine in the treatment of head and neck cancer.
-
CEL-SCI Files Request With the UK’s MHRA Regarding Path to Approval for Multikine in the Treatment of Head & Neck Cancer
10/5/2023
CEL-SCI Corporation (NYSE American: CVM) today reported it has filed a request with the United Kingdom’s Medicines and Healthcare Products Regulatory Agency (MHRA) to discuss a pathway for approval of Multikine* (Leukocyte Interleukin, Injection) immunotherapy for the treatment of newly diagnosed head and neck cancer.
-
CEL-SCI Submits Scientific Advice Filing to European Medicines Agency (EMA) for Multikine in the Treatment of Head & Neck Cancer
9/26/2023
CEL-SCI Corporation reported it has filed a request for Scientific Advice regarding Multikine* immunotherapy for the treatment of newly diagnosed locally advanced squamous cell carcinoma of the head and neck with the European Medicines Agency’s Scientific Advice Working Group.
-
CEL-SCI Corporation Reports Third Quarter Fiscal 2023 Financial Results
8/11/2023
CEL-SCI Corporation (NYSE American: CVM) today reported financial results for the quarter ended June 30, 2023, as well as key clinical and corporate developments.
-
CEL-SCI Announces Closing of Public Offering - July 20, 2023
7/20/2023
CEL-SCI Corporation announced the closing of its previously announced public offering of 2,500,000 shares of its common stock at a public offering price of $2.00 per share, for gross proceeds of $5,000,000, before deducting underwriting discounts and offering expenses.
-
CEL-SCI Announces Pricing of Public Offering - July 18, 2023
7/18/2023
CEL-SCI Corporation, a Phase 3 cancer immunotherapy company, announced the pricing of an underwritten public offering of 2,500,000 shares of its common stock at a public offering price of $2.00 per share, for gross proceeds of $5,000,000, before deducting underwriting discounts, and offering expenses.
-
CEL-SCI Announces Proposed Public Offering of Common Stock - July 17, 2023
7/17/2023
CEL-SCI Corporation, a Phase 3 cancer immunotherapy company, announced that it intends to offer to sell shares of its common stock in an underwritten public offering.
-
CEL-SCI Concludes Positive Meeting With U.S. FDA Concerning Multikine’s Approval for Head & Neck Cancer
7/14/2023
CEL-SCI Corporation (NYSE American: CVM) today announced it has concluded a productive meeting with the U.S. Food and Drug Administration (FDA) regarding the path forward for bringing Multikine* (Leukocyte Interleukin, Injection) immunotherapy to market for the treatment of newly diagnosed locally advanced squamous cell carcinoma of the head and neck (SCCHN).
-
CEL-SCI Reports Phase 3 Tumor PD-L1 Biomarker Data Demonstrate Multikine’s Increased Efficacy and Points to Potential for Combination With Checkpoint Inhibitors for Head & Neck Cancer
7/11/2023
CEL-SCI Corporation (NYSE American: CVM) today announced new data from a biomarker analysis of its pivotal Phase 3 study in newly diagnosed locally advanced squamous cell carcinoma of the head and neck (SCCHN) at the American Head and Neck Cancer Society’s (AHNS) 11th Annual International Conference.